MMP19 and cancer: The efficacy of RASi as an adjunctive cancer treatment has been corroborated by numerous studies, which collectively analyzed 11,739 patients and reported a combined hazard ratio of 0.85 and a PFS of 0.91, highlighting the beneficial impact of RAS inhibitors on cancer patients [57].